Sampre Nutritions Limited (530617) Fair Value & Analysis
Other · IN · Market cap ₹51.1M
Fair value as of: Aug 9, 2026
From 15 valuation models · updated 4 days ago
Fair value updated Aug 9, 2026, revised from ₹95.81 to ₹6.48 (−93.2%) since Jul 4, 2026. Share price −18.3% over the past month.
Below-average quality, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- A fairly wide model range (₹4.54 to ₹8.43) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 9, 2026.
How to read this chart
60‑month range ₹3.48 – ₹70.56 · fair‑value band ₹4.54 – ₹8.43 · the ₹6.13 price screens below the ₹6.48 fair value. Dashed = 300-day average. As of Aug 9, 2026.
Analysis
Sampre Nutritions Limited (530617) currently trades at ₹6.13, while our model-based Fair Value estimate is ₹6.48, implying the stock looks roughly 5.7% fairly valued today. The Quality Score stands at 30/100 (below-average quality), in the Other sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Sampre Nutritions Limited generated revenue of ₹214M at a net margin of -3.9%. Revenue declined 67.3% year over year. Net debt stands at ₹178M. The stock trades on a trailing P/E of 39.1. Fundamentals as of Aug 9, 2026
Our scenario range runs from ₹4.54 (bear case) to ₹8.43 (bull case); at ₹6.13, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Other peers we cover trades at -22% fair-value upside, at 6%, 530617 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 15 models by family
Widest divergence: Asset-Based (₹149.23) versus Economic Profit (₹14.23). Highest evidence: ROIC Compounder (72).
Notify me when 530617 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 32 · Market factors (momentum, volatility) 19
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Sampre Nutritions Limited manufactures and sells sugar confectionery products in India. It offers éclairs, candies, toffees, powder, and center filled products primarily to MNCs. The company sells its products under Sampre brand name. Sampre Nutritions Limited was incorporated in 1991 and is based in Hyderabad, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Sampre Nutritions Limited reported revenue of ₹433M in FY2026 versus ₹231M in FY2022, a compound +17.0%/yr. Reported net income was ₹30.8M in FY2026, compounding +77.8%/yr from FY2022.
Watch 530617: get an alert when its fair value changes →
Peer Group
Other · 394 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Other median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Other stocks, each showing price versus our Fair Value estimate (as of Aug 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Federal Home Loan Mortgage Corporation FREJO | $15.84 | $52.77 | +233% |
| 533278 533278 | ₹411.00 | ₹660.78 | +61% |
| Nestl?? India Limited 500790 | ₹1,459 | ₹191.93 | -87% |
| 540376 540376 | ₹4,044 | ₹1,538 | -62% |
| 540777 540777 | ₹537.85 | ₹149.72 | -72% |
| Lupin Limited 500257 | ₹2,476 | ₹1,983 | -20% |
| 540719 540719 | ₹1,845 | ₹877.00 | -52% |
| 524804 524804 | ₹1,620 | ₹1,268 | -22% |
| 540716 540716 | ₹1,612 | ₹1,224 | -24% |
| Eicher Motors Limited 505200 | ₹7,340 | ₹6,859 | -7% |
Compare Sampre Nutritions Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
Frequently asked questions
Is Sampre Nutritions Limited (530617) overvalued or undervalued?
What is the fair value of 530617?
What is the quality score of 530617?
What is the revenue of Sampre Nutritions Limited (530617)?
What is the net profit margin of 530617?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Sampre Nutritions Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.